The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness in perioperative therapy in the era of immune checkpoint inhibitors.
 
Masahiro Fujioka
No Relationships to Disclose
 
Toshihiko Aranishi
Employment - Lilly Japan
Stock and Other Ownership Interests - Eli Lilly and company, Chugai Pharmaceutical Co., Ltd.
 
Takehito Shukuya
Honoraria - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nippon kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Chugai Pharma; MSD; Novartis
 
Yukina Shirai
No Relationships to Disclose
 
Kazuhisa Takahashi
Honoraria - Amgen; AstraZeneca; AstraZeneca; BioMerieux Japan Ltd.; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Eisai; Kyorin; Kyorin; Lilly Japan; MSD K.K; MSD K.K; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Shionogi; Shionogi; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Thermo Fisher Scientific; Viatris
Speakers' Bureau - AstraZeneca; Chugai Pharma; Chugai Pharma; Kyorin; Novartis; Ono Pharmaceutical
Research Funding - Chugai Pharma; Chugai Pharma; MSD K. K.; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical